Listed by the USPTO as KELLY, ROBERT M
Tech Center 1600 • Art Units: 1615 1631 1633 1638 1651 1654 1656
This examiner grants 74% of resolved cases
KELLY, ROBERT M handles prosecution in Tech Center 1600 and Art Unit 1615. The profile covers 953 resolved cases, with a 74.0% allowance rate and a 24.4% interview lift. Those figures indicate a substantial examination record in which interviews are associated with a meaningful increase in allowance outcomes. The allowance rate is materially higher than the interview lift, so the overall disposition record provides the broader signal for evaluating prosecution strategy.
The median time to allowance is 1058 days. Practitioners should therefore account for a lengthy prosecution cycle when planning claim amendments, continuation timing, and client expectations. The listed companies include Figene LLC, The Regents of the University of California, and Krystal Biotech Inc. The listed firms are NORTON ROSE FULBRIGHT US LLP, Casimir Jones, S.C., and MARSHALL, GERSTEIN & BORUN LLP. These organizations identify recurring participants in the available case record and can provide useful context when benchmarking matters before this examiner.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18745400 | PLATFORM FOR GENERATING SAFE CELL THERAPEUTICS | Non-Final OA | The Regents of the University of California |
| 18342642 | METHODS OF TREATING LYSOSOMAL DISORDERS | Final Rejection | The Regents of the University of California |
| 18942735 | COMMENSAL FUNGUS AND USES THEREOF | Non-Final OA | YEDA RESEARCH AND DEVELOPMENT CO. LTD. |
| 18818917 | MOTOR UNIT CHIP, MANUFACTURING METHOD THEREOF AND METHOD OF DETECTING PATHOLOGICAL EVENT USING THE SAME | Non-Final OA | REGENTS OF THE UNIVERSITY OF MINNESOTA |
| 18587729 | METHODS FOR ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 18467826 | PHARMACEUTICAL COMPOSITION FOR TREATING NON-ALCOHOLIC FATTY LIVER, NON-ALCOHOLIC STEATOHEPATITIS, OR HEPATIC FIBROSIS USING SSU72 PROTEIN OR A POLYNUCLEOTIDE ENCODING THE SAME | Final Rejection | RESEARCH & BUSINESS FOUNDATION SUNGKYUNKWAN UNIVERSITY |
| 17767856 | ONCOLYTIC VIRUSES THAT EXPRESS MULTI-SPECIFIC IMMUNE CELL ENGAGERS | Final Rejection | Arizona Board of Regents on Behalf of Arizona State University |
| 19147007 | COMPOSITIONS COMPRISING SUPRAMOLECULAR ASSEMBLIES OF PEPTIDE AMPHIPHILES AND ORGANIC CATIONS AND METHODS OF USE THEREOF | Non-Final OA | Northwestern University |
| 18511568 | DYSTROPHIN CONSTRUCTS CONTAINING R11-R12 | Non-Final OA | THE CURATORS OF THE UNIVERSITY OF MISSOURI |
| 18545176 | Combination Treatment | Non-Final OA | Duke University |
| 18527005 | COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS TO CELLS | Non-Final OA | Yale University |
| 17829087 | RESTIMULATION OF CRYOPRESERVED TUMOR INFILTRATING LYMPHOCYTES | Final Rejection | Iovance Biotherapeutics Inc. |
| 18699193 | METHODS FOR PREVENTING INTER-DROPLET TRANSFER OF A FLUORESCENT PRODUCT IN AQUEOUS DROPLETS BY FORMING A SOLUBLE COMPLEX WITH CYCLODEXTRIN | Final Rejection | PATTERN BIOSCIENCE, INC. |
| 18703201 | METHODS OF USE AND ADMINISTRATION OF ENCAPSULATED CELLS | Non-Final OA | William Marsh Rice University |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy74.0% of resolved applications examined by Robert M Kelly were allowed (953 resolved cases), compared with 43.8% across Art Unit 1615 over the last five years.
This examiner's interview lift is +24.4 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Robert M Kelly took 1,058 days on average from filing to allowance.
Robert M Kelly examines applications in Art Unit 1615 in Tech Center 1600 (Biotechnology & Pharmaceuticals).